Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind placebo-controlled trial of sublingual CBD:THC oil for hospitalized patients with moderate to severe COVID-19
MOH_2023-05-01_012592Phase 2Not yet recruiting
- Sponsor
- Raphael Pharmaceutical
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing CBD:THC oil + standard of care with Placebo oil + standard of care (2 arms). Planned start Mar 2023; status: not yet recruiting.
02
Drugs
cannabidioldronabinol
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on MOH_2023-05-01_012592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-05-01_012592.